Skip to main content
. 2017 Sep 6;11:2643–2651. doi: 10.2147/DDDT.S122417

Table 2.

223Ra toxicity in patients with metastatic castration-resistant prostate cancer

Toxicities (grade 3/4) Phase II study35 n=100 Phase II study28 n=122 Phase III study29 n=921 223Ra vs placebo Phase III-b study32 Retrospective study33
Hematological
 Anemia 8% 7% 13% vs 13% 12% 5%
 Thrombocytopenia 6% 2% 12% vs 6% 3% 5%
 Neutropenia 3% <1% 3% vs 1% 2% 4%
Gastrointestinal
 Diarrhea NR 0 25% vs 15% 1% NR
 Nausea NR 0 2% vs 2% <1% NR

Abbreviations: 233Ra, radium-223; NR, not reported.